Insurance companies sits at the center of this dementia and brain health question.

Insurance companies are not yet covering dementia blood tests as of March 2026, but the landscape is changing rapidly. Mississippi just became a flashpoint for this shift by passing “Jill’s Law” on March 12, 2026—legislation that requires state-regulated insurance plans, private insurers, Medicaid, and Medicare to cover Alzheimer’s biomarker testing for people with symptoms. This state-level action reflects a broader trend: insurers and policymakers are beginning to recognize that blood-based dementia tests offer something traditional brain imaging cannot—affordable, early detection that can identify disease 3 to 4 years before symptoms appear.

While coverage remains limited today, the momentum is undeniable. Twenty states already have laws requiring biomarker testing coverage, another 13 states have introduced similar legislation, and a bipartisan federal bill called the ASAP Act is moving through Congress to authorize federal coverage decisions. This article explores why insurance companies are turning their attention to dementia blood tests, how much they actually cost compared to existing alternatives, and what this shift means for families trying to access early detection today.

Why the Price of Dementia Blood Tests Is Forcing Insurers’ Hands
How State Legislation Is Creating a Domino Effect
The Blood Test That Changed the Conversation
The Current Reality: No Coverage Yet, But Growing Access
How Insurance Coverage Varies by Plan and State
Why Blood Tests Attract Insurance Coverage Faster Than Imaging
What the Next Wave of Coverage Expansion Might Look Like
Conclusion

Why the Price of Dementia Blood Tests Is Forcing Insurers’ Hands

The core reason insurance companies are starting to pay attention is economics. A state-of-the-art dementia blood test—specifically tests measuring plasma phosphorylated tau (p-tau217)—carries a list price of $1,450. That sounds expensive until you compare it to what insurers currently cover for detecting Alzheimer’s pathology. Amyloid PET imaging costs $3,000 to $7,000 per scan. Cerebrospinal fluid biomarker tests, which require a lumbar puncture, also fall into that $3,000 to $7,000 range. When a blood test can do the same diagnostic work for one-third the cost, insurance company actuaries take notice.

The financial pressure is real and quantifiable—insurers cover brain imaging regularly, so approving blood tests at roughly 20 cents on the dollar becomes hard to justify refusing, especially as volume increases and per-test costs decline further. However, cost advantage alone doesn’t automatically trigger coverage. Insurers also need to see that a test actually changes medical outcomes. This is where the timing of recent scientific advances becomes crucial. Tests using p-tau217 now predict Alzheimer’s symptoms 3 to 4 years in advance, according to research published in February 2026. That lead time opens a window for interventions—newer Alzheimer’s drugs like lecanemab are most effective in early stages, and doctors can now counsel families, arrange support systems, and initiate treatment before symptoms begin. Insurance companies recognize this: a test that enables early intervention is more valuable than one that simply confirms what symptoms already suggest.

Why the Price of Dementia Blood Tests Is Forcing Insurers' Hands

How State Legislation Is Creating a Domino Effect

Mississippi’s passage of “Jill’s Law” represents the most aggressive legislative push to date. The law doesn’t ask insurance companies to consider coverage or study the issue—it mandates it. State-regulated insurance plans, private insurers offering plans in Mississippi, Medicaid, and even Medicare (for Mississippi beneficiaries) must cover Alzheimer’s biomarker testing for symptomatic individuals. This is significant because it removes the insurance company’s veto. For decades, insurers have declined to cover emerging diagnostic tests, waiting for perfect evidence or cost reductions. Mississippi changed that calculus by passing the decision out of corporate hands and into state law. Mississippi is not alone. As of May 2025, 20 states already had laws requiring biomarker testing coverage in place.

That number has grown, with 13 additional states having introduced legislation modeled on similar frameworks. The legislative momentum creates pressure on insurance companies operating across multiple states: they cannot maintain different coverage policies in every state forever. At some point, the compliance burden and market pressure push them toward national coverage decisions. The federal ASAP Act takes this concept national, proposing that the Department of Health and Human Services gain the authority to cover routine blood-based dementia screening tests that meet FDA approval standards. If passed, this would bypass the current state-by-state patchwork and establish federal policy similar to how Medicare covers screening colonoscopies or mammograms. The key limitation: Even with state laws in place, implementation lags behind legislation. Insurers can take months or years to create billing codes, establish medical policies, and train claims processors. Mississippi passed its law recently, but actual coverage may not reach beneficiaries immediately. Families in states without such legislation still face coverage denials today.

The Blood Test That Changed the Conversation

The clinical foundation for this coverage push is the p-tau217 blood test, a biomarker that detects Alzheimer’s pathology in the brain by measuring a specific form of tau protein in the blood. ARUP Laboratories, a major clinical laboratory, launched its p-tau217 test on April 21, 2025, making it available for patients age 60 and older. This test represents a breakthrough because it doesn’t require brain imaging, hospital visits, or invasive procedures. A simple blood draw at a primary care office can identify patients who have amyloid and tau accumulation in their brains—the hallmarks of Alzheimer’s disease—years before cognitive decline becomes noticeable. The predictive power is what matters to insurers and neurologists alike. Recent research published in February 2026 showed that p-tau217 levels in blood can forecast the onset of Alzheimer’s symptoms 3 to 4 years into the future. For a patient without memory complaints today but with an elevated p-tau217 result, this creates an actionable window.

A neurologist can establish a baseline, monitor cognitive function regularly, initiate preventive treatments like lecanemab early, and work with the patient and family on care planning. Insurance companies understand that this kind of early intervention, especially with newly approved disease-modifying drugs, could reduce downstream costs associated with advanced Alzheimer’s care—institutionalization, behavioral crises, emergency room visits, and prolonged caregiver strain. However, the test is not a silver bullet. An elevated p-tau217 result indicates pathology but not inevitably symptomatic dementia. Some people with amyloid and tau in their brains never develop cognitive impairment during their lifetime. Insurers are grappling with whether to cover testing in asymptomatic individuals or only those with memory complaints. Most current legislation and insurance discussions center on symptomatic patients—those who already have mild cognitive impairment or subjective cognitive concerns. Testing asymptomatic individuals for future risk remains ethically and economically contentious.

The Blood Test That Changed the Conversation

The Current Reality: No Coverage Yet, But Growing Access

As of March 2026, despite the legislative momentum and scientific advances, no blood-based biomarker tests are currently covered by public or private insurers. This is the critical fact that confuses many families: you can get the test, but you will likely pay out of pocket. A p-tau217 test ordered through ARUP or other laboratories may cost $1,450 at full list price, though many laboratories negotiate lower cash-pay rates for self-pay patients. Some offer sliding-scale pricing or payment plans for families without coverage. The practical path for families right now involves several steps. First, discuss cognitive concerns with a primary care physician or neurologist. If testing seems appropriate, ask the provider to check current insurance coverage policies—some insurers have quietly begun covering tests on a case-by-case basis, and policies vary by plan and state.

Second, if insurance denies coverage, ask for an itemized quote directly from the laboratory. ARUP and other labs often reduce prices for uninsured patients compared to the list price. Third, consider whether your state has passed biomarker testing coverage legislation; if so, you may have grounds to appeal an insurance denial. Fourth, for patients without insurance or facing financial hardship, some neurological centers and academic medical centers offer testing at reduced rates or as part of research studies. The comparison to other diagnostic tests is instructive. Genetic testing for breast cancer risk (BRCA1/BRCA2) was not covered by most insurers in the late 1990s either, yet it is now standard coverage for high-risk patients. The pathway involved clinical validation, cost reduction, demonstrated impact on medical decisions, and gradual insurance policy changes. Dementia blood tests are following a similar trajectory, but accelerated by legislative intervention.

How Insurance Coverage Varies by Plan and State

The emerging coverage landscape is fragmented, and this fragmentation creates confusion. State-level mandates like Mississippi’s Jill’s Law apply to insurance plans regulated or sold within that state, but they do not affect plans operated by self-insured employers that fall under federal ERISA law. Large corporations often self-insure their health plans, meaning they pay claims directly rather than purchasing insurance. These self-insured plans are exempt from state insurance mandates unless the employer chooses to adopt the same coverage policies. This creates a situation where a Mississippi resident working for a large national employer might not have coverage even though their state law nominally requires it. Medicare’s role adds another layer of complexity. Medicare is federal, not state-regulated, so state biomarker testing laws don’t directly apply to Medicare beneficiaries.

However, Medicare can make its own coverage decisions independent of state laws. Some recent signals suggest Medicare is warming to coverage of dementia biomarker tests, particularly for symptomatic beneficiaries, but no official decision has been announced as of March 2026. For Medicaid—state-run programs that cover low-income individuals—each state determines whether to implement biomarker testing coverage, and adoption has been uneven. Some states with insurance mandates have not extended the same coverage to Medicaid. Private insurers operating across multiple states face pressure to establish consistent national policies. A large insurer cannot easily maintain coverage in Massachusetts and denial in Ohio, as this creates operational headaches and regulatory exposure. Expect major insurers to move toward national coverage of dementia blood tests within the next 1 to 2 years, driven by this administrative pressure and the expanding state legislative trend. However, if X is that you have a narrow-network plan or a plan offered by a small insurer, then Y is that your insurer may lag behind larger competitors in adopting coverage.

How Insurance Coverage Varies by Plan and State

Why Blood Tests Attract Insurance Coverage Faster Than Imaging

The insurance and regulatory world has historical precedent for prioritizing blood tests over imaging when both can answer the same clinical question. Consider the rise of troponin blood tests for detecting heart attacks—these replaced or reduced reliance on cardiac imaging and became standard coverage decades ago. Similarly, PSA blood tests for prostate cancer screening became covered early, despite controversy. The reasons are practical: blood tests are cheaper, faster, don’t require specialized equipment or facilities, and generate fewer billing disputes. An imaging center can code a PET scan incorrectly or provide unnecessary follow-up scans. A laboratory blood test has a clear, defensible code and a straightforward pathway from order to result.

For dementia biomarker testing, this logic applies directly. A patient can have blood drawn at a routine office visit or at home by a phlebotomist, mailed to a laboratory, and results delivered to the physician’s office without hospitalization, sedation, or radiation exposure. From an insurance company’s perspective, this is administratively elegant. From a patient’s perspective, it’s accessible. Insurance companies cover things that are cheap, repeatable, and aligned with their operational strengths. Dementia blood tests tick all three boxes, which is why legislation and industry movement are converging on coverage more rapidly than anyone predicted five years ago.

What the Next Wave of Coverage Expansion Might Look Like

If the pattern of state legislation continues—and given the current momentum, that is likely—expect a critical mass of states to have biomarker testing coverage laws by the end of 2026 or early 2027. This will create sufficient market pressure that private insurers and Medicare will likely follow suit rather than maintain complex state-by-state carve-outs. The likely sequence: first, symptomatic patients with cognitive complaints will achieve broad insurance coverage. Second, asymptomatic individuals with family history of Alzheimer’s may become a covered category, though this will be more contentious.

Third, as the list of available biomarker tests expands beyond p-tau217 to include other tau variants and amyloid measures, insurers will need to establish protocols for which tests are covered and when. The federal ASAP Act, if passed, would accelerate and standardize this process. Rather than waiting for state-by-state adoption, a federal mechanism would allow the FDA to approve dementia blood tests and HHS to establish uniform coverage policy nationwide. This model has worked for cancer screening tests and other preventive diagnostics. The timeline remains uncertain—Congress moves slowly—but the bipartisan support suggests serious legislative intent.

Conclusion

Insurance companies are beginning to cover dementia blood tests not because of altruism but because the economics and science align: these tests cost one-quarter to one-third of existing imaging alternatives, they predict disease 3 to 4 years in advance, and they enable early intervention with newly approved treatments. Mississippi’s Jill’s Law and similar legislation in 20 states are crystallizing this shift from “research tool” to “covered service.” However, families should know that comprehensive coverage does not exist uniformly yet—legislation is ahead of implementation, and most insurers still deny claims as of March 2026.

The pathway forward involves checking your own insurance policy, exploring state law protections if you live in a covered state, and discussing access options with your healthcare provider if coverage is denied. Over the next 1 to 2 years, coverage is likely to expand significantly as administrative pressure mounts and federal policy evolves. For now, the transition is underway, but the journey to universal access is not complete.